Back to results
US 2005/0033034 A1Published application
Anti-t cell immunotoxin fusion protein and its therapeutic use
OwnerGunter Engelinventor
Life of this patent
Estimating the term…
Abstract
A combination comprising (a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells and (b) at least one chemotherapeutic agent.
Claims17
A combination comprising:
- (a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells;
- and
- (b) at least one chemotherapeutic agent comprising:
- (i) an antineoplastic agent selected from the group consisting of:
- aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase 11 inhibitors, microtubule active agents, busulfan, ifosfamide, melphalan, 5-fluorouracil, cytarabine, fludarabine, capecitabine, gemcitabine, edatrexate, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bisphosphonates, trastuzumab, 6-thioguanidine, hydroxyurea, procarbazine and bleomycin;
- or
- (ii) an agent used as an adjuvant in cancer therapy.
4 more elements
A pharmaceutical composition comprising:
- (a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells;
- and
- (b) at least one chemotherapeutic agent comprising:
- (i) an antineoplastic agent selected from the group consisting of:
- aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase 11 inhibitors, microtubule active agents, busulfan, ifosfamide, melphalan, 5-fluorouracil, cytarabine, fludarabine, capecitabine, gemcitabine, edatrexate, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bisphosphonates, trastuzumab, 6-thioguanidine, hydroxyurea, procarbazine and bleomycin;
- or
- (ii) an agent used as an adjuvant in cancer therapy.
4 more elements
6-9. (canceled)
Dependencies are inferred from the claim text.